Clinical trial
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly…
NCT00089167 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00089167 |
|---|---|
| Title | Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis |
| Official title | Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, dexamethasone, melphalan, thalidomide |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2007 |
| First posted | Aug 5, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: